1. An accessible pharmacodynamic transcriptional biomarker for notch target engagement. Issue 4 (17th February 2016) Authors: Tanis, KQ; Podtelezhnikov, AA; Blackman, SC; Hing, J; Railkar, RA; Lunceford, J; Klappenbach, JA; Wei, B; Harman, A; Camargo, LM; Shah, S; Finney, EM; Hardwick, JS; Loboda, A; Watters, J; Bergstrom, DA; Demuth, T; Herman, GA; Strack, PR; Iannone, R Journal: Clinical pharmacology & therapeutics Issue: Volume 99:Issue 4(2016:Apr.) Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042. (15th December 2019) Authors: Herbst, R S; Lopes, G; Kowalski, D M; Kasahara, K; Wu, Y-L; De Castro, G; Cho, B C; Turna, H Z; Cristescu, R; Aurora-Garg, D; Lunceford, J; Kobie, J; Ayers, M; Pietanza, M C; Piperdi, B; Mok, T S K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. (15th December 2019) Authors: Gadgeel, S; Rodriguez-Abreu, D; Felip, E; Esteban, E; Speranza, G; Reck, M; Hui, R; Boyer, M; Garon, E B; Horinouchi, H; Cristescu, R; Aurora-Garg, D; Lunceford, J; Kobie, J; Ayers, M; Piperdi, B; Pietanza, M C; Garassino, M C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗